Amlodipine Besylate And Atorvastatin Calcium
Product Images NDC 54868-6335

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate And Atorvastatin Calcium (NDC 54868-6335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (10 mg/80 mg Tablet Label)

A pharmacy label for amlodipine besylate and atorvastatin calcium 10/80 mg tablets distributed by Physicians Total Care, Inc. It indicates a package containing 30 tablets with the product NDC 54868-6335-0. The label includes a lot number and expiration date, along with a barcode for scanning.*

FDA Label Image

Chemical Structure (Amlodipine 01)

Chemical structure diagram of the active ingredient amlodipine besylate and atorvastatin calcium, showing molecular bonds and groups in a black-and-white line drawing format.*

FDA Label Image

Chemical Structure (Amlodipine 02)

Chemical structure diagram of atorvastatin calcium, depicted as the calcium salt with three water molecules. The structure shows the arrangement of atoms and bonds representing the atorvastatin molecule complexed with calcium.*

FDA Label Image

Figure 1 (Amlodipine 03)

A Kaplan-Meier survival curve comparing event rates over time (in months) between two groups: Placebo and Amlodipine. The y-axis shows event rate, and the x-axis represents months up to 24. The plot includes a p-value of 0.003, hazard ratio of 0.691, and 95% confidence interval from 0.54 to 0.88, indicating statistical analysis of event occurrence differences between the groups.*

FDA Label Image

Figure 2 (Amlodipine 04)

A forest plot displaying hazard ratios and 95% confidence intervals comparing amlodipine versus placebo across various patient subgroups. Categories include age, gender, baseline sitting systolic blood pressure, vessel disease, vessel stenosis, and PCI-stent strata. The plot shows summary markers for each subgroup favoring either amlodipine or placebo, with a vertical line at hazard ratio 1.0 representing no effect.*

FDA Label Image

Figure 3 (Amlodipine 05)

A line graph showing cumulative incidence percentage over 3.5 years comparing Atorvastatin and Placebo groups. The solid line represents Atorvastatin with a lower cumulative incidence than the dashed Placebo line. The graph includes hazard ratio (HR=0.64) and p-value (p=0.0005) indicating statistical significance.*

FDA Label Image

Figure 4 (Amlodipine 06)

A cumulative hazard plot comparing atorvastatin and placebo treatment groups over approximately 48 months. The x-axis represents time to first primary endpoint in months, and the y-axis shows cumulative hazards. A hazard ratio of 0.63 with a 95% confidence interval of 0.48 to 0.83 is indicated, demonstrating differences between the two groups over the follow-up period.*

FDA Label Image

Figure 5 (Amlodipine 07)

A line graph comparing the time to first major cardiovascular endpoint (in years) between two doses of atorvastatin calcium (80 mg and 10 mg). The y-axis shows the subset percentage experiencing the event. The graph includes patient numbers, event counts, censoring percentages, hazard ratio (0.78), confidence interval, and p-values, illustrating a lower event rate for the 80 mg dose over about 5.5 years.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.